Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?

Transplantation Reviews

Volumn 27, Issue 3, 2013, Pages 76-84

  Zuckermann, Andreas ^a   Wang, Shoei Shen ^b   Epailly, Eric ^c   Barten, Markus J ^d   Sigurdardottir, Vilborg ^e   Segovia, Javier ^f   Varnous, Shaida ^g   Turazza, Fabio M ^h   Potena, Luciano ⁱ   Lehmkuhl, Hans B ^j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c HÔPITAL CIVIL   (France)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j DEUTSCHES HERZZENTRUM BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ATTENUATION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELL DIFFERENTIATION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETIC PATIENT; DRUG EFFICACY; DRUG EXPOSURE; GRAFT FAILURE; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY FUNCTION; KIDNEY PRESERVATION; LYMPHOCELE; MAINTENANCE THERAPY; MEMORY T LYMPHOCYTE; MULTICENTER STUDY (TOPIC); PERICARDIAL EFFUSION; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURGICAL WOUND; WOUND COMPLICATION; WOUND HEALING;

EID: 84880131323     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.03.002     Document Type: Review

References (82)

1. Schaffer S.A., Ross H.J. Everolimus: efficacy and safety in cardiac transplantation. Expert Opin Drug Saf 2010, 9:843-854.
2. Manito N., Delgado J.F., Crespo-Leiro M.G., et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev (Orlando) 2010, 24:129-142.
3. Eisen H, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomised, multicentre trial. Am J Transplant 2013. [Epub ahead of print]. http://dx.doi.org/10.1111/ajt.12181.
4. Zuckermann A., Wang S.S., Ross H., et al. Efficacy and safety of low-dose cyclosporine with everolimus and steroids in de novo heart transplant patients: a multicentre, randomized trial. J Transplant. 2011, 2011:535983.
5. Lehmkuhl H.B., Arizon J., Viganò M., et al. 2411 Study Investigators: everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009, 88:115-122.
6. Wang S.S., Chou N.K., Chi N.H., et al. Can cyclosporine blood level be reduced to half after heart transplantation?. Transplant Proc 2010, 42:930-933.
7. Gullestad L., Iversen M., Mortensen S.A., et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010, 89:864-872.
8. Potena L., Bianchi I.G., Magnani G., et al. Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study. Transplantation 2010, 89:263-265.
9. Epailly E., Albanell J., Andreassen A., et al. Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. Clin Transplant 2011, 25:E475-E486.
10. Ross H., Pflugfelder P., Haddad H., et al. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients. J Heart Lung Transplant 2008, 27:197-202. CADENCE Study Group.
11. Gude E., Gullestad L., Arora S., et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010, 29:641-647.
12. Boffini M., Sansone F., Patanè F., et al. Does everolimus associated with a low dose of cyclosporine in long-term cardiac transplant recipients improve renal function? Initial experience. Transplant Proc 2009, 41:1349-1352.
13. Fuchs U., Zittermann A., Hakim-Meibodi K., et al. Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study. Transplant Proc 2011, 43:1839-1846.
14. Schweiger M., Wasler A., Prenner G., et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transpl Immunol 2006, 16:46-51.
15. Moro J., Almenar L., Martínez-Dolz L., et al. mTOR inhibitors: do they help preserve renal function?. Transplant Proc 2007, 39:2135-2137.
16. Behnke-Hall K., Bauer J., Thul J., et al. Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus. Pediatr Transplant 2011, 15:784-789.
17. Sánchez-Brotons J.A., Sobrino-Márquez J.M., Lage-Gallé E., et al. Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy. Transplant Proc 2008, 40:3046-3048.
18. Moro López J.A., Almenar L., Martínez-Dolz L., et al. Progression of renal dysfunction in cardiac transplantation after the introduction of everolimus in the immunosuppressive regime. Transplantation 2009, 87:538-541.
19. Stypmann J., Engelen M.A., Eckernkemper S., et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2years' follow-up from the University Hospital Münster. Transplant Proc 2011, 43:1847-1852.
20. Rothenburger M., Teerling E., Bruch C., et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6months' follow-up. J Heart Lung Transplant 2007, 26:250-257.
21. Parisi F., Branzi A., Fiocchi R., et al. Study design and preliminary results of the Italian Everolimus Registry CERTIC. J Heart Lung Transplant 2012, 31(Suppl.):S223-S224.
22. Arora S., Erikstad I., Ueland T., et al. Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus - results of a multicenter trial. Am J Transplant 2012, 12:2700-2709.
23. Euvrard S., Boissonnat P., Roussoulières A., et al. Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients. Transpl Int 2010, 23:855-857.
24. Lehmkuhl H., Hetzer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin. J Heart Lung Transplant 2005, 24(4 Suppl):S201. [discussion S210].
25. Lehmkuhl H.B., Mai D., Dandel M., et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007, 26:700-704.
26. Wang S.S., Chou N.K., Chi N.H., et al. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate. Transplant Proc 2010, 42:938-939.
27. Wang S.S., Chou N.K., Chi N.H., et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. Transplant Proc 2008, 40:2607-2608.
28. Chou N.K., Wang S.S., Chen Y.S., et al. Induction immunosuppression with basiliximab in heart transplantation. Transplant Proc 2008, 40:2623-2625.
29. Wang S.S., Chou N.K., Chi N.H., et al. Clinical experience of tacrolimus with everolimus in heart transplantation. Transplant Proc 2012, 44:907-909.
30. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847-858. RAD B253 Study Group.
31. Nashan B., Curtis J., Ponticelli C., et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year Phase II, randomized, multicenter, open-label study. Transplantation 2004, 78:1332-1340.
32. Starling R.C., Hare J.M., Hauptman P., et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant 2004, 4:2126-2131.
33. Gonzalez-Vilchez F., de Prada J.A., Exposito V., et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008, 27:1135-1141.
34. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy?. Curr Control Trials Cardiovasc Med 2000, 1:166-171.
35. Colvin-Adams M., Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant 2011, 25:175-184.
36. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005, 24:945-955.
37. Azzola A., Havryk A., Chhajed P., et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004, 77:275-280.
38. Hiemann N.E., Wellnhofer E., Knosalla C., et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 2007, 116:1274-1282.
39. Akselband Y., Harding M.W., Nelson P.A. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991, 23:2833-2836.
40. Humar R., Kiefer F.N., Berns H., et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002, 16:771-780.
41. Schuurman H.-J., Pally C., Weckbecker G., et al. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 1999, 31:1024-1025.
42. Matsumoto Y., Hof A., Baumlin Y., et al. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid artery allografts in apolipoprotein E-deficient mice. Transplantation 2003, 76:1166-1170.
43. Cassese S., Piccolo R., Galasso G., et al. Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials. Int J Cardiol 2011, 150:84-89.
44. Kalesan B., Stefanini G.G., Räber L., et al. Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes. JACC Cardiovasc Interv 2012, 5:145-154.
45. Räber L., Jüni P., Nüesch E., et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol 2011, 57:2143-2151.
46. Hiemann N.E., Wellnhofer E., Lehmkuhl H.B., et al. Everolimus prevents endomyocardial remodeling after heart transplantation. Transplantation 2011, 92:1165-1172.
47. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005, 45:1532-1537.
48. Viganò M., Tuzcu M., Benza R., et al. RAD B253 Study Group: prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007, 26:584-592.
49. Lee C.M., Wu Y.W., Jui H.Y., et al. Intravascular ultrasound correlates with coronary flow reserve and predicts the survival in angiographically normal cardiac transplant recipients. Cardiology 2008, 109:93-98.
50. Kobashigawa J.A. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant 2003, 22:711-714.
51. Tuzcu E.M., Kapadia S.R., Sachar R., et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005, 45:1538-1542.
52. Eisen H., Yang X. The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation. Transplantation 2006, 82(8S):S13-S18.
53. Arora S., Ueland T., Wennerblom B., et al. Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation 2011, 92:235-243.
54. da Cunha-Bang C., Sørensen S.S., Iversen M., et al. Factors associated with the development of cytomegalovirus infection following solid organ transplantation. Scand J Infect Dis 2011, 43:360-365.
55. Snydman D.R., Limaye A.P., Potena L., Zamora M.R. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc 2011, 43(3 Suppl):S1-S17.
56. Potena L., Valantine H.A. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007, 20:425-431.
57. Webster A.C., Lee V.W., Chapman J.R., et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006, 81:1234-1248.
58. Brennan D.C., Legendre C., Patel D., et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011, 11:2453-2462.
59. Kobashigawa J., Ross H., Bara C., et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis 2013, 15:150-162.
60. Viganò M., Dengler T., Mattei M.F., et al. RAD A2411 Study Investigators: lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl Infect Dis 2010, 12:23-30.
61. Hill J.A., Hummel M., Starling R.C., et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007, 84:1436-1442.
62. Poglitsch M., Weichhart T., Hecking M., et al. CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. Am J Transplant 2012, 12:1458-1468.
63. Araki K., Turner A.P., Shaffer V.O., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
64. Araki K., Youngblood B., Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2010, 235:234-243.
65. Arora S., Gude E., Sigurdardottir V., et al. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. J Heart Lung Transplant 2012, 31:259-265.
66. Holdaas H., Rostaing L., Serón D., et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 2011, 92:410-418. ASCERTAIN Investigators.
67. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
68. Sully K., Akinduro O., Philpott M.P., et al. The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling. Oncogene 2012, [Epub ahead of print]. 10.1038/onc.2012.338.
69. Zuckermann A., Manito N., Epailly E., et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Lung Heart Transplant 2008, 27:141-149.
70. Zuckermann A., Barten M.J. Surgical wound complications after heart transplantation. Transplant Int 2011, 24:627-636.
71. Pengel L.H., Liu L.Q., Morris P.J. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transplant Int 2011, 24:1216-1230.
72. Zuckermann A., Arizon J.M., Dong G., et al. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation 2011, 92:594-600.
73. Albano L., Berthoux F., Moal M.C., et al. RAD A2420 Study Group: incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009, 88:69-76.
74. Potena L., Rinaldi M., Maiello C., et al. Early vs delayed everolimus in de novo heart transplant recipients. J Heart Lung Transplant 2011, 30(4 Supp):S35.
75. Quin J.A., Tauriainen M.P., Huber L.M., et al. Predictors of pericardial effusion after orthotopic heart transplantation. J Thorac Cardiovasc Surg 2002, 124:979-983.
76. Hauptman P.J., Couper G.S., Aranki S.F., et al. Pericardial effusions after cardiac transplantation. J Am Coll Cardiol 1994, 23:1625-1629.
77. Al-Dadah A.S., Guthrie T.J., Pasque M.K., et al. Clinical course and predictors of pericardial effusion following cardiac transplantation. Transplant Proc 2007, 39:1589-1592.
78. Ciliberto G.R., Anjos M.C., Gronda E., et al. Significance of pericardial effusion after heart transplantation. Am J Cardiol 1995, 76:297-300.
79. Gullestad L., Mortensen S.A., Eiskjær H., et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010, 90:1581-1589.
80. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Study Investigators: tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6:1377-1386.
81. Kuypers D.R. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008, 13:11-18.
82. Pascual J., del Castillo D., Cabello M., et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. Transplantation 2010, 89:994-1000.